These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9651728)

  • 21. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications.
    Dávila DF; Núñez TJ; Odreman R; de Dávila CA
    Int J Cardiol; 2005 Jun; 101(3):343-6. PubMed ID: 15907399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroendocrine responses to acute myocardial infarction.
    Levine AB; Levine TB
    Henry Ford Hosp Med J; 1991; 39(3-4):151-4. PubMed ID: 1804818
    [No Abstract]   [Full Text] [Related]  

  • 23. Renal function as a predictor of prognosis in chronic heart failure.
    Hillege H; Van Gilst W; de Zeeuw D; van Veldhuisen DJ
    Heart Fail Monit; 2002; 2(3):78-84. PubMed ID: 12634888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Catecholamine levels and treatment in chronic heart failure.
    Anker SD
    Eur Heart J; 1998 Jun; 19 Suppl F():F56-61. PubMed ID: 9651737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pathophysiology of congestive heart failure].
    Luzza F; Bruni F; Rizzo F; Carerj S
    Minerva Cardioangiol; 2002 Jun; 50(3):209-19. PubMed ID: 12107401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methods to quantify sympathetic cardiovascular influences.
    Mancia G; Daffonchio A; Di Rienzo M; Ferrari AU; Grassi G
    Eur Heart J; 1998 Jun; 19 Suppl F():F7-13. PubMed ID: 9651729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathophysiology of heart failure update: the role of neurohumoral activation in the progression of heart failure.
    Moser DK
    AACN Clin Issues; 1998 May; 9(2):157-71. PubMed ID: 9633270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sympathetic activation in chronic renal failure.
    Schlaich MP; Socratous F; Hennebry S; Eikelis N; Lambert EA; Straznicky N; Esler MD; Lambert GW
    J Am Soc Nephrol; 2009 May; 20(5):933-9. PubMed ID: 18799718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular consequences of loss of supraspinal control of the sympathetic nervous system after spinal cord injury.
    Teasell RW; Arnold JM; Krassioukov A; Delaney GA
    Arch Phys Med Rehabil; 2000 Apr; 81(4):506-16. PubMed ID: 10768544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of catecholamines and sympathetic activation as a risk factor for coronary artery disease.
    Amadi A; Ponikowski P; Coats AJ
    J Cardiovasc Risk; 1995 Jun; 2(3):222-8. PubMed ID: 7584797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limitations of the use of spectral analysis of heart rate variability for the estimation of cardiac sympathetic activity in heart failure.
    Notarius CF; Floras JS
    Europace; 2001 Jan; 3(1):29-38. PubMed ID: 11271948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine changes in heart failure and their clinical relevance.
    Parmley WW
    Clin Cardiol; 1995 Aug; 18(8):440-5. PubMed ID: 7586761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recognized molecular mechanisms of heart failure: approaches to treatment.
    Ceconi C; Cargnoni A; Curello S; Ferrari R
    Rev Port Cardiol; 1998 Oct; 17 Suppl 2():II79-91. PubMed ID: 9835784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Activation of the renin-angiotensin-aldosterone system in heart failure].
    Volpe M; Tocci G; Pagannone E
    Ital Heart J; 2005 May; 6 Suppl 1():16S-23S. PubMed ID: 15945296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model.
    Nap A; Belterman CN; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):220-7. PubMed ID: 14689369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease.
    Mancia G; Dell'Oro R; Quarti-Trevano F; Scopelliti F; Grassi G
    J Hypertens Suppl; 2006 Mar; 24(1):S51-6. PubMed ID: 16601574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sympathetic activation in cardiovascular and renal disease.
    Grassi G; Arenare F; Pieruzzi F; Brambilla G; Mancia G
    J Nephrol; 2009; 22(2):190-5. PubMed ID: 19384835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-blockers in heart failure.
    Cohn JN
    Eur Heart J; 1998 Jun; 19 Suppl F():F52-5. PubMed ID: 9651736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The sympathetic nervous system in congestive cardiac insufficiency].
    Muiesan G
    Recenti Prog Med; 1967 Oct; 43(4):329-37. PubMed ID: 5632725
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of beta 1-partial agonist(ICI 118-587) on plasma catecholamines level and hemodynamics during exercise in congestive heart failure].
    Sato H; Matsuyama T; Ozaki H; Fukushima M; Matsumoto M
    Kokyu To Junkan; 1984 Nov; 32(11):1159-62. PubMed ID: 6151727
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.